Trial Profile
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs FATE NK100 (Primary) ; Cetuximab; Trastuzumab
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms DIMENSION
- Sponsors Fate Therapeutics
- 18 Nov 2021 Status changed from active, no longer recruiting to completed.
- 07 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 29 Jan 2019 Planned End Date changed from 1 Mar 2020 to 1 Oct 2022.